Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

Stopped early · Phase 2

Conditions studied: Colorectal Cancer

In brief

RATIONALE: Monoclonal antibodies such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with capecitabine work in treating patients with metastatic colorectal cancer.

Key facts

Study ID

NCT00538291

Run by

City of Hope Medical Center

People needed

13

Starts

2005-08-01

Last updated by the study team

2014-08-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• City of Hope Medical Group — Pasadena, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.